Genetically predicted testosterone and electrocardiographic QT interval duration in Chinese: A Mendelian randomization analysis in the Guangzhou Biobank Cohort Study

International Journal of Epidemiology

Volumn 44, Issue 2, 2015, Pages 613-620

  Zhao, Jie ^a   Jiang, Chaoqiang ^b   Lam, Tai Hing ^a   Liu, Bin ^b   Cheng, Kar Keung ^c   Xu, Lin ^a   Long, Mei Jing ^a   Zhang, Weisen ^b   Leung, Gabriel M ^a   Schooling, C Mary ^a,d  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b Guangzhou Number 12 Hospital   (China)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Mendelian randomization; QT interval; Testosterone

Indexed keywords

TESTOSTERONE; AROMATASE; CYP19A1 PROTEIN, HUMAN;

CARDIOVASCULAR DISEASE; COHORT ANALYSIS; ELECTRICAL METHOD; GENETIC ANALYSIS; HEALTH RISK; MORTALITY RISK; POLYMORPHISM; RISK ASSESSMENT; TESTOSTERONE;

ADULT; ARTICLE; CHINESE; COHORT ANALYSIS; DISEASE ASSOCIATION; ELECTROCARDIOGRAPHY; FRAMINGHAM RISK SCORE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; HEART RATE; HONG KONG; HUMAN; INSTRUMENTAL VARIABLE ANALYSIS; MAJOR CLINICAL STUDY; MENDELIAN RANDOMIZATION ANALYSIS; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; QTC INTERVAL; SINGLE NUCLEOTIDE POLYMORPHISM; AGE DISTRIBUTION; AGED; CHINA; EPIDEMIOLOGY; ETHNOLOGY; GENETICS; MALE; MIDDLE AGED; VERY ELDERLY;

CHINA; GUANGDONG; GUANGZHOU; HONG KONG;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AROMATASE; CHINA; COHORT STUDIES; ELECTROCARDIOGRAPHY; HEART RATE; HONG KONG; HUMANS; MALE; MENDELIAN RANDOMIZATION ANALYSIS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TESTOSTERONE;

EID: 84936764512     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyu241     Document Type: Article

References (58)

1. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013;380:2095-128.
2. Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 1991;83:1888-94.
3. Zhang Y, Post WS, Blasco-Colmenares E, Dalal D, Tomaselli GF, Guallar E. Electrocardiographic QT interval and mortality: a meta-analysis. Epidemiology 2011;22:660-70.
4. Rautaharju PM, Zhou SH, Wong S et al. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol 1992;8:690-95.
5. van Noord C, Dorr M, Sturkenboom MC et al. The association of serum testosterone levels and ventricular repolarization. Eur J Epidemiol 2010;25:21-28.
6. Fox KM, Ferrari R. Heart rate: a forgotten link in coronary artery disease? Nat Rev Cardiol 2011;8:369-79.
7. Zhang Y, Ouyang P, Post WS et al. Sex-steroid hormones and electrocardiographic QT-interval duration: findings from the third National Health and Nutrition Examination Survey and the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol 2011;174:403-11.
8. Schooling CM, Zhao J, Zhang Y. The association of androgens with QT interval and heart rate in US men. Int J Cardiol 2014; 177:592-4.
9. Drici MD, Burklow TR, Haridasse V, Glazer RI, Woosley RL. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 1996;94:1471-74.
10. Marques Neto SR, da H Silva A, dos Santos MC, Ferraz EF, Nascimento JH. The blockade of angiotensin AT1 and aldosterone receptors protects rats from synthetic androgen-induced cardiac autonomic dysfunction. Acta Physiol (Oxf) 2013;208:166-71.
11. White CM, Ferraro-Borgida MJ, Moyna NM et al. The effect of pharmacokinetically guided acute intravenous testosterone administration on electrocardiographic and blood pressure variables. J Clin Pharmacol 1999;39:1038-43.
12. Malkin CJ, Morris PD, Pugh PJ, English KM, Channer KS. Effect of testosterone therapy on QT dispersion in men with heart failure. Am J Cardiol 2003;92:1241-43.
13. Chung T, Kelleher S, Liu PY, Conway AJ, Kritharides L, Handelsman DJ. Effects of testosterone and nandrolone on cardiac function: a randomized, placebo-controlled study. Clin Endocrinol (Oxf) 2007;66:235-45.
14. Rosano GM, Leonardo F, Pagnotta P et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 1999;99:1666-70.
15. Tolcher AW, Chi KN, Shore ND et al. Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol 2012;70:305-13.
16. Fulop L, Banyasz T, Szabo G et al. Effects of sex hormones on ECG parameters and expression of cardiac ion channels in dogs. Acta Physiol (Oxf) 2006;188:163-71.
17. Eleawa SM, Sakr HF, Hussein AM, Assiri AS, Bayoumy NM, Alkhateeb M. Effect of testosterone replacement therapy on cardiac performance and oxidative stress in orchidectomized rats. Acta Physiol (Oxf) 2013;209:136-47.
18. Schwartz JB, Volterrani M, Caminiti G et al. Effects of testosterone on the Q-T interval in older men and older women with chronic heart failure. Int J Androl 2011;34(5 Pt 2):e415-21.
19. Feldman HA, Longcope C, Derby CA et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002;87:589-98.
20. Shi Z, Araujo AB, Martin S, O'Loughlin P, Wittert GA. Longitudinal changes in testosterone over five years in community-dwelling men. J Clin Endocrinol Metab 2013;98:3289-97.
21. Haring R, Teumer A, Volker U et al. Mendelian randomization suggests non-causal associations of testosterone with cardiometabolic risk factors and mortality. Andrology 2013;1:17-23.
22. Zhao J, Jiang C, Lam TH et al. Genetically predicted testosterone and cardiovascular risk factors in men: a Mendelian randomization analysis in the Guangzhou Biobank Cohort Study. Int J Epidemiol 2014;43:140-48.
23. Schwartz LM, Woloshin S. Low 't' as in 'template': how to sell disease. JAMA Intern Med 2013;173:1460-62.
24. Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy. Testosterone and Aging Clinical Research Directions. Washington, DC: National Academies Press, 2004.
25. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013;11:108.
26. Handelsman DJ. Global trends in testosterone prescribing, 2000-2011: expanding the spectrum of prescription drug misuse. Med J Aust 2013;199:548-51.
27. Health Canada. Summary Safety Review-Testosterone Replacement Products-Cardiovascular Risk. http://www.hcsc.gc.ca/dhp-mps/medeff/reviews-examens/testosterone-eng.php. (5 December 2014, date last accessed).
28. Food and Drug Administration. Panel Backs Limits on Testosterone Drugs. 2014. http://www.nytimes.com/2014/09/18/health/testosterone-drugs-fda.html?_r=0. (19 September 2014, date last accessed).
29. Jiang C, Thomas GN, Lam TH et al. Cohort Profile: The Guangzhou Biobank Cohort Study, a Guangzhou-Hong Kong-Birmingham collaboration. Int J Epidemiol 2006;35:844-52.
30. Capital Bio Corporation. http://science.capitalbio.com/khfbwz/smkxfwxg/index.shtml. (5 December 2014, date last accessed).
31. Long MJ, Jiang CQ, Lam TH et al. Alcohol consumption and electrocardiographic left ventricular hypertrophy and mediation by elevated blood pressure in older Chinese men: the Guangzhou Biobank Cohort Study. Alcohol 2013;47:473-80.
32. Long MJ, Jiang CQ, Lam TH et al. Atrial fibrillation and obesity among older Chinese: the Guangzhou Biobank Cohort Study. Int J Cardiol 2011;148:48-52.
33. Sagie A, Larson MG, Goldberg RJ, Bengtson JR, Levy D. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol 1992;70:797-801.
34. Bazett HC. An analysis of time relations of electrocardiograms. Heart 1920;7:353-67.
35. Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is 'normal'. J Cardiovasc Electrophysiol 2006;17:333-36.
36. Johnson JN, Ackerman MJ. QTc: how long is too long? Br J Sports Med 2009;43:657-62.
37. Tchetgen Tchetgen EJ, Walter S, Glymour MM. Commentary: building an evidence base for mendelian randomization studies: assessing the validity and strength of proposed genetic instrumental variables. Int J Epidemiol 2013;42:328-31.
38. Stock JH, Yogo M. Testing for Weak Instruments in Linear IV Regression. Cambridge, MA: National Bureau of Economic Research, 2002.
39. Pierce BL, Burgess S. Efficient design for mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol 2013;178:1177-84.
40. Schooling CM, Au Yeung SL, Freeman G. Mendelian randomization estimates may be inflated. J AmColl Cardiol 2013;61:1931.
41. Bennett DA. An introduction to instrumental variables-part 2: Mendelian randomisation. Neuroepidemiology 2010;35:307-10.
42. Mangoni AA, Kinirons MT, Swift CG, Jackson SH. Impact of age on QT interval and QT dispersion in healthy subjects: a regression analysis. Age Ageing 2003;32:326-31.
43. Mason JW, Ramseth DJ, Chanter DO, Moon TE, Goodman DB, Mendzelevski B. Electrocardiographic reference ranges derived from 79,743 ambulatory subjects. J Electrocardiol 2007;40:228-34.
44. Anttonen O, Junttila MJ, Rissanen H, Reunanen A, Viitasalo M, Huikuri HV. Prevalence and prognostic significance of short QT interval in a middle-aged Finnish population. Circulation 2007;116:714-20.
45. Wu J, Kors JA, Rijnbeek PR, van Herpen G, Lu Z, Xu C. Normal limits of the electrocardiogram in Chinese subjects. Int J Cardiol 2003;87:37-51.
46. Chen Z, Tao S, Gao Y et al. Genome-wide association study of sex hormones, gonadotropins and sex hormone-binding protein in Chinese men. J Med Genet 2013;50:794-801.
47. Fernandez-Balsells MM, Murad MH, Lane M et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:2560-75.
48. Kivimaki M, Magnussen CG, Juonala M et al. Conventional and Mendelian randomization analyses suggest no association between lipoprotein(a) and early atherosclerosis: the Young Finns Study. Int J Epidemiol 2011;40:470-78.
49. Davey Smith G, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 2004;33:30-42.
50. Burgess S, Thompson SG, Collaboration CCG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol 2011;40:755-64.
51. Johnson RC, Nelson GW, Troyer JL et al. Accounting for multiple comparisons in a genome-wide association study (GWAS). BMC Genomics 2010;11:724.
52. Feise RJ. Do multiple outcome measures require p-value adjustment? BMC Med Res Methodol 2002;2:8.
53. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998;316:1236-38.
54. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48.
55. Vandenput L, Labrie F, Mellstrom D et al. Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. J Bone Miner Res 2007;22:220-7.
56. Labrie F, Cusan L, Gomez JL et al. Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer. J Steroid Biochem Mol Biol 2009;113:52-56.
57. Schooling CM. Androgen activity, ischaemic heart disease and risk factors among men in NHANES III. Eur J Clin Invest 2013;43:1273-81.
58. Maior AS, Menezes P, Pedrosa RC, Carvalho DP, Soares PP, Nascimento JH. Abnormal cardiac repolarization in anabolic androgenic steroid users carrying out submaximal exercise testing. Clin Exp Pharmacol Physiol 2010;37:1129-33.